Who owns enVVeno Medical Corporation?
Institutional ownership of NVNO from SEC Form 13F filings across 15 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
15
13F holders
$571,104
value, 2026 filers
321.3%
of shares outstanding (53,002 sh)
3
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of NVNO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 36,166 | $387,338 | 0.0% | 219.2% | 0.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6,287 | $67,397 | 0.0% | 38.1% | -50.0% |
| 3 | JPMORGAN CHASE & CO | 5,208 | $59,111 | 0.0% | 31.6% | 0.0% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 2,184 | $23,412 | 0.0% | 13.2% | 0.0% |
| 5 | Westside Investment Management, Inc. | 1,525 | $16,332 | 0.0% | 9.2% | -4.0% |
| 6 | Mirae Asset Global Investments Co., Ltd.NEW | 539 | $5,773 | 0.0% | 3.3% | new |
| 7 | BlackRock, Inc. | 414 | $4,434 | 0.0% | 2.5% | -77.5% |
| 8 | Tower Research Capital LLC (TRC) | 331 | $3,545 | 0.0% | 2% | -38.9% |
| 9 | WELLS FARGO & COMPANY/MN | 114 | $1,221 | 0.0% | 0.7% | 0.0% |
| 10 | Allied Private Wealth LLCNEW | 88 | $978 | 0.0% | 0.5% | new |
| 11 | Vanguard Global Advisers, LLC | 77 | $825 | 0.0% | 0.5% | 0.0% |
| 12 | MORGAN STANLEY | 59 | $632 | 0.0% | 0.4% | -22.4% |
| 13 | OSAIC HOLDINGS, INC. | 7 | $74 | 0.0% | 0% | 0.0% |
| 14 | BARCLAYS PLCNEW | 2 | $21 | 0.0% | 0% | new |
| 15 | UBS Group AG | 1 | $11 | 0.0% | 0% | -99.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.